Trinity Biotech plc (NASDAQ:TRIB) Short Interest Update

Trinity Biotech plc (NASDAQ:TRIB) was the recipient of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 159,300 shares, a decline of 59.9% from the February 13th total of 396,900 shares. Based on an average daily volume of 2,090,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.5% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on shares of Trinity Biotech in a report on Friday. They issued a “sell” rating for the company.

Hedge Funds Weigh In On Trinity Biotech

A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC grew its position in shares of Trinity Biotech plc (NASDAQ:TRIB) by 5.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 378,590 shares of the company’s stock after acquiring an additional 18,780 shares during the quarter. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 78.97% of the company’s stock.

Trinity Biotech Trading Up 0.9 %

Trinity Biotech stock traded up $0.01 during mid-day trading on Friday, reaching $0.69. The company’s stock had a trading volume of 17,199 shares, compared to its average volume of 916,063. Trinity Biotech has a twelve month low of $0.63 and a twelve month high of $3.55. The firm has a market cap of $12.37 million, a price-to-earnings ratio of -0.30 and a beta of 1.20. The business has a 50 day moving average price of $0.81 and a 200-day moving average price of $1.19.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.